Mofegiline
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
(2E)-2-(fluoromethylidene)-4-(4-fluorophenyl)butan-1-amine
|
|
| Clinical data | |
| Routes of administration |
Oral[1] |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Biological half-life | 1–3 hours[1] |
| Excretion | Urine[2] |
| Identifiers | |
| CAS Number | 119386-96-8 |
| ATC code | None |
| PubChem | CID 6437850 |
| ChemSpider | 4942371 |
| UNII | 1FMJ6D8Y1B |
| Synonyms | MDL-72,974A |
| Chemical data | |
| Formula | C11H13F2N |
| Molar mass | 197.224 g/mol |
|
|
|
Mofegiline (MDL-72,974) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) and semicarbazide-sensitive amine oxidase (SSAO) which was under investigation for the treatment of Parkinson's disease and Alzheimer's disease,[3][4][5][6] but was never marketed.[7]
Synthesis[edit]
See also[edit]
References[edit]
- ^ a b Stoltz M, Reynolds D, Elkins L, Salazar D, Weir S (September 1995). "Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial". Clinical Pharmacology and Therapeutics 58 (3): 342–53. doi:10.1016/0009-9236(95)90252-X. PMID 7554709.
- ^ Dulery BD, Schoun J, Zreika M, et al. (March 1993). "Pharmacokinetics of and monoamine oxidase B inhibition by (E)-4-fluoro-beta-fluoromethylene benzene butanamine in man". Arzneimittel-Forschung 43 (3): 297–302. PMID 8489556.
- ^ Palfreyman MG, McDonald IA, Bey P, Schechter PJ, Sjoerdsma A (1988). "Design and early clinical evaluation of selective inhibitors of monoamine oxidase". Progress in Neuro-psychopharmacology & Biological Psychiatry 12 (6): 967–87. doi:10.1016/0278-5846(88)90092-9. PMID 3266532.
- ^ Zreika M, Fozard JR, Dudley MW, Bey P, McDonald IA, Palfreyman MG (1989). "MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease". Journal of Neural Transmission. Parkinson's Disease and Dementia Section 1 (4): 243–54. doi:10.1007/bf02263478. PMID 2597310.
- ^ Palfreyman MG, McDonald IA, Bey P, Danzin C, Zreika M, Cremer G (1994). "Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential". Journal of Neural Transmission. Supplementum 41: 407–14. doi:10.1007/978-3-7091-9324-2_54. ISBN 978-3-211-82521-1. PMID 7931257.
- ^ Thiffault C, Quirion R, Poirier J (March 1998). "Effect of the MAO-B inhibitor, MDL72974, on superoxide dismutase activity and lipid peroxidation levels in the mouse brain". Synapse 28 (3): 208–11. doi:10.1002/(SICI)1098-2396(199803)28:3<208::AID-SYN3>3.0.CO;2-E. PMID 9488505.
- ^ Ganellin, C. R.; Triggle, D. J.; Macdonald, F. (1997). Dictionary of pharmacological agents. CRC Press. p. 1370. ISBN 978-0-412-46630-4. Retrieved 25 November 2011.
- ^ McDonald, Ian A.; Lacoste, Jean Michel; Bey, Philippe; Palfreyman, Michael G.; Zreika, Monique (1985). "Enzyme-activated irreversible inhibitors of monoamine oxidase: Phenylallylamine structure-activity relationships". Journal of Medicinal Chemistry 28 (2): 186. doi:10.1021/jm00380a007. PMID 3968682.
- ^ I. A. McDonald, M. G. Palfreyman, EP 295604 (1988 to Merrell Dow).
|
|
|
|
